Through GIP and GLP-1 receptor activation, it not only addresses hunger but also enhances your metabolic profile, making it a powerful ally in the battle against obesity
For instance, on December 2, 2024, the American Diabetes Association (ADA) released a guidance statement on the use of compounded GLP-1 RA (glucagon-like peptide-1 receptor agonist) and dual GIP/GLP-1 RA (glucose-dependent insulinotropic polypeptide and GLP-1 RA) medication classes
Clinical trial data shows nausea affects between 15.4% to 43.9% of users depending on dose and formulation, with higher doses producing increased incidence
NMN and NR work by boosting NAD+ levels, which in turn fuels the mitochondria
Phytomedicine 62, 152950
Niu S, Alkhuzam KA, Guan D, et al